Quarterly report pursuant to Section 13 or 15(d)

Segments (Details)

v3.5.0.2
Segments (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue $ 6,690,090 $ 2,952,522 $ 14,704,489 $ 6,751,492  
Lymphoseek license revenue 1,295,625 550,000 1,795,625 883,333  
Grant and other revenue 511,359 476,755 2,113,995 1,320,816  
Total revenue 8,497,074 3,979,277 18,614,109 8,955,641  
Cost of goods sold, excluding depreciation and amortization 909,539 442,094 1,950,644 1,167,141  
Research and development expenses, excluding depreciation and amortization 1,276,053 3,900,638 6,461,154 10,169,900  
Selling, general and administrative expenses, excluding depreciation and amortization 2,841,587 3,827,393 9,613,582 13,137,061  
Depreciation and amortization 111,464 132,229 378,834 431,368  
Income (loss) from operations 3,358,431 (4,323,077) 209,895 (15,949,829)  
Other income (expense), excluding equity in the loss of R-NAV, LLC (3,417,967) (3,721,242) (10,621,828) (8,808,202)  
Equity in the loss of R-NAV, LLC   (26,785) (15,159) (295,217)  
Net income (loss) (59,536) (8,071,104) (10,427,092) (25,053,248)  
Total assets, net of depreciation and amortization 11,189,600   11,189,600   $ 14,964,513
Payments to Acquire Property, Plant, and Equipment 1,847 2,788 1,847 30,406  
United States [Member]          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 6,670,644 2,942,498 14,660,670 6,736,418  
Total assets, net of depreciation and amortization 11,040,679 17,042,641 11,040,679 17,042,641  
International [Member]          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 19,446 10,024 43,819 15,074  
Total assets, net of depreciation and amortization 148,921 440,816 148,921 440,816  
Corporate [Member]          
Segment Reporting Information [Line Items]          
Selling, general and administrative expenses, excluding depreciation and amortization 1,974,419 2,721,844 6,594,918 8,381,910  
Depreciation and amortization 99,186 115,216 311,992 223,870  
Income (loss) from operations (2,073,605) (2,837,060) (6,906,910) (8,605,780)  
Other income (expense), excluding equity in the loss of R-NAV, LLC (3,417,967) (3,721,242) (10,621,828) (8,808,202)  
Equity in the loss of R-NAV, LLC   (26,785) (15,159) (295,217)  
Net income (loss) (5,491,572) (6,585,087) (17,543,897) (17,709,199)  
Payments to Acquire Property, Plant, and Equipment 1,847 2,788 1,847 4,914  
Corporate [Member] | United States [Member]          
Segment Reporting Information [Line Items]          
Total assets, net of depreciation and amortization 6,357,898 13,291,939 6,357,898 13,291,939  
Corporate [Member] | International [Member]          
Segment Reporting Information [Line Items]          
Total assets, net of depreciation and amortization 697 467 697 467  
Diagnostics [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Lymphoseek license revenue 1,295,625 550,000 1,795,625 883,333  
Grant and other revenue 501,013 476,755 2,052,197 1,320,816  
Total revenue 8,486,728 3,979,277 18,552,311 8,955,641  
Cost of goods sold, excluding depreciation and amortization 909,539 442,094 1,950,644 1,167,141  
Research and development expenses, excluding depreciation and amortization 1,028,389 3,603,501 5,860,364 9,610,012  
Selling, general and administrative expenses, excluding depreciation and amortization 839,410 1,063,062 2,987,074 4,634,279  
Depreciation and amortization 12,278 17,013 66,842 207,498  
Income (loss) from operations 5,697,112 (1,146,393) 7,687,387 (6,663,289)  
Net income (loss) 5,697,112 (1,146,393) 7,687,387 (6,663,289)  
Payments to Acquire Property, Plant, and Equipment       25,492  
Diagnostics [Member] | Operating Segments [Member] | United States [Member]          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 6,670,644 2,942,498 14,660,670 6,736,418  
Total assets, net of depreciation and amortization 4,673,425 3,750,702 4,673,425 3,750,702  
Diagnostics [Member] | Operating Segments [Member] | International [Member]          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 19,446 10,024 43,819 15,074  
Total assets, net of depreciation and amortization 148,224 440,349 148,224 440,349  
Therapeutics [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Grant and other revenue 10,346   61,798    
Total revenue 10,346   61,798    
Research and development expenses, excluding depreciation and amortization 247,664 297,137 600,790 559,888  
Selling, general and administrative expenses, excluding depreciation and amortization 27,758 42,487 31,590 120,872  
Income (loss) from operations (265,076) (339,624) (570,582) (680,760)  
Net income (loss) (265,076) $ (339,624) (570,582) $ (680,760)  
Therapeutics [Member] | Operating Segments [Member] | United States [Member]          
Segment Reporting Information [Line Items]          
Total assets, net of depreciation and amortization $ 9,356   $ 9,356